Alumis Inc. (ALMS)
(Delayed Data from NSDQ)
$12.87 USD
+0.16 (1.26%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $12.88 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Alumis Inc. (ALMS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$27.50 | $36.00 | $13.00 | 116.37% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Alumis Inc. comes to $27.50. The forecasts range from a low of $13.00 to a high of $36.00. The average price target represents an increase of 116.37% from the last closing price of $12.71.
Analyst Price Targets (4 )
Broker Rating
Alumis Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to no recommendation a month ago.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. There was no Strong Buy or Buy recommendation a month ago.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | NA | NA | NA |
Buy | 0 | 0 | NA | NA | NA |
Hold | 0 | 0 | NA | NA | NA |
Sell | 0 | 0 | NA | NA | NA |
Strong Sell | 0 | 0 | NA | NA | NA |
ABR | 1.00 | 1.00 | NA | NA | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/23/2024 | Guggenheim Securities | Yatin Suneja | Not Available | Strong Buy |
7/23/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Not Available | Strong Buy |
7/23/2024 | SVB Securities | Thomas J Smith | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $27.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -1.20 |